Human trials start for China's new COVID-19 vaccine | Article | China Daily
RT Banner 2021V4.gif

China Daily

News> Nation> Content
Sunday, April 25, 2021, 12:45
Human trials start for China's new COVID-19 vaccine
By Xinhua
Sunday, April 25, 2021, 12:45 By Xinhua

A sample of the COVID-19 inactivated vaccine is seen at a vaccine production plant of China National Pharmaceutical Group (Sinopharm) in Beijing, capital of China, April 10, 2020. (PHOTO / Xinhua)

BEIJING - Sinopharm, the Chinese pharmaceutical giant, has commenced phase-1 and phase-2 clinical trials for its new recombinant vaccine against COVID-19 in central China's Henan province.

This is the CNBG's third COVID-19 vaccine candidate approved for human trials

Developed by the China National Biotec Group (CNBG), a Sinopharm's bioscience subsidiary, the vaccine was issued with a clinical research permit from the National Medical Products Administration on April 9.

READ MORE: Mainland reports 13 new COVID-19 cases, all imported

This is the CNBG's third COVID-19 vaccine candidate approved for human trials.

Researchers started the early-staged clinical trials in the city of Shangqiu, Henan Province. The trials were randomized, double-blind and placebo-controlled, according to a company statement.

ALSO READ: Mainland reports 9 new COVID-19 cases, all imported

Zhang Yuntao, vice president of the CNBG, said the recombinant vaccine candidate has been genetically engineered. Unlike the company's inactivated COVID-19 vaccines, the new one does not need a high-grade biosafety laboratory for manufacture, and it can quickly achieve large-scale production.

"It is designed for people aged three and above," Zhang said.

Whether the gene recombinant vaccine should be administered in three doses will be determined by the results of clinical trials, Zhang added.

Share this story

CHINA DAILY
HONG KONG NEWS
OPEN
Please click in the upper right corner to open it in your browser !